eTheRNA immunotherapies NV

Activities: Pharmaceutical

Trending Articles

  1. Navin Molecular constructs a new R&D facility in Dewas, India The laboratory will enhance the CDMO's small molecule laboratory- and kilo-scale process development capabilities, as well as its analytical development and testing capacity
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    The ABCs of ADCs: manufacturing ultra-high potent active ingredients Senior Technical Manager at Sterling Pharma Solutions, Matt Miklas, presents a pragmatic approach to the safe and cost-effective production of highly potent pharmaceutical...
  3. Pharmapack predicts how the pharmaceutical market will operate in 2025 Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a record year in 2025
  4. Servier expands AI partnership with Google Cloud to bolster pharma R&D efforts The company will utilise AI and generative AI technology to optimise its therapeutic target/drug discovery and development processes
  5. Cytiva and Cellular Origins team up to advance the cell and gene therapy manufacturing process By combining Cytiva's Sefia platform with Cellular Origins' automated Constellation platform, the two will help its customers to efficiently scale up CGT production to...

Upcoming event

Pharmapack

22 – 23 January 2025 | Exhibition | Paris, France See all

Related Content

Research & Development

etherna and Dropshot team up to optimise the RNA drug development process in $950m deal

The two companies will combine their LNP and mRNA-based technologies to develop precision medicines for cardiac and renal diseases
Manufacturing

etherna appoints Antonin de Fougerolles as new Chairperson

Tony has extensive experience in the development of novel therapeutic modalities, such as RNAis and modified mRNAs for vaccinations
Research & Development

etherna and Hasselt University collaborate to develop mRNA-based therapies for autoimmune disease

The collaboration will aim to develop treatments for multiple sclerosis, and is backed by Flanders Innovation & Entrepreneurship (VLAIO)
Manufacturing

etherna appoints Shelly West as Business Development Director, US

Shelly arrives from Cellpoint Biosciences and will be in charge of expanding etherna's US customer base
Ingredients

LNP formulation improves mRNA vaccine efficacy and tolerability

S-Ac7-DOG encapsulated mRNA demonstrated markedly higher transfection, lower reactogenicity, and higher accumulation in the vaccine draining lymph nodes
Research & Development

Almirall and etherna to develop mRNA-based therapies in medical dermatology

The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
Manufacturing

eTheRNA Manufacturing announces LNP development service

The service uses the company’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions
Subscribe now